The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Abstract
Background/objectives: Neurofilament light chain (NfL) levels in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients correlate with the degree of neuronal injury. To date, little is known about NfL concentrations in the serum of relapsing remitting multiple sclerosis (RRMS) patients and their relationship with CSF levels and magnetic resonance imaging (MRI) measures of disease severity. We aimed to validate the quantification of NfL in serum samples of RRMS, as a biofluid source easily accessible for longitudinal studies. Methods: A total of 31 RRMS patients underwent CSF and serum sampling. After a median time of 3.6 years, 19 of these RRMS patients, 10 newly recruited RRMS patients and 18 healthy controls had a 3T MRI and serum sampling. NfL concentrations were determined by electrochemiluminescence immunoassay. Results: NfL levels in serum were highly correlated to levels in CSF ( r = 0.62, p = 0.0002). Concentrations in serum were higher in patients than in controls at baseline ( p = 0.004) and follow-up ( p = 0.0009) and did not change over time ( p = 0.56). Serum NfL levels correlated with white matter (WM) lesion volume ( r = 0.68, p < 0.0001), mean T1 ( r = 0.40, p = 0.034) and T2* relaxation time ( r = 0.49, p = 0.007) and with magnetization transfer ratio in normal appearing WM ( r = −0.41, p = 0.029). Conclusion: CSF and serum NfL levels were highly correlated, and serum concentrations were increased in RRMS. Serum NfL levels correlated with MRI markers of WM disease severity. Our findings further support longitudinal studies of serum NfL as a potential biomarker of on-going disease progression and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes of NfL in bodily fluids have been linked to brain damage and brain atrophy in mouse models and multiple neurological disorders including proteopathic neurodegenerative diseases11,13–16.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [16]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Noseworthy, J. H., Lucchinetti, C. F., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 3,016
Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement
Lee, J. W., Devanarayan, V., Barrett, Y. C., WEINER, R. S., Allinson, J. L., Fountain, S. T., Keller, S., Weinryb, I., Green, M., Duan, L., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9045-3 · Cited by 771
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Myelin and iron concentration in the human brain: a quantitative study of MRI contrast
Stüber, C., Morawski, M., Schäfer, A., Labadie, C., Wähnert, M., Leuze, C., Streicher, M., Barapatre, N., Reimann, K., Geyer, S., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.02.026 · Cited by 635
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J. H., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 493
Self-citationConcepts of myelin and myelination in neuroradiology.
Barkovich, A. J. (2000) · PubMed Central · Cited by 460
Neurochemical Aftermath of Amateur Boxing
Zetterberg, H., Hietala, M. A., Jonsson, M. A. G., Andreasen, N., Styrud, E., Karlsson, I., Edman, Å., Popa, C., Rasulzada, A., Wahlund, L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1277 · Cited by 366
Cited by
Sorted by citations
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Self-citationDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationBlood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kühle, J., Kropshofer, H., Häring, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Self-citationBarro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Self-citationNeurofilaments: neurobiological foundations for biomarker applications
Gafson, A., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J., Kühle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 339
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 304
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalbán, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 308
The potential of serum neurofilament as biomarker for multiple sclerosis
Bittner, S., Oh, J., Havrdová, E., Tintoré, M., & Zipp, F. (2021) · Brain · doi:10.1093/brain/awab241 · Cited by 235
Siller, N., Kühle, J., Muthuraman, M., Barro, C., Uphaus, T., Groppa, S., Kappos, L., Zipp, F., & Bittner, S. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518765666 · Cited by 213
Self-citationSerum neurofilament is associated with progression of brain atrophy and disability in early MS
Kühle, J., Nourbakhsh, B., Grant, D., Morant, S. V., Barro, C., Yaldizli, Ö., Pelletier, D., Giovannoni, G., Waubant, E. L., & Gnanapavan, S. (2017) · Neurology · doi:10.1212/wnl.0000000000003653 · Cited by 203
Self-citationCantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2137 · Cited by 199
Self-citationPiehl, F., Kockum, I. S., Khademi, M., Blennow, K., Lycke, J., Zetterberg, H., & Olsson, T. P. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517715132 · Cited by 184
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
Högel, H., Rissanen, E., Barro, C., Matilainen, M., Nylund, M., Kühle, J., & Airas, L. M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518819380 · Cited by 176
Self-citationNeurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Bergman, J., Dring, A. M., Zetterberg, H., Blennow, K., Norgren, N., Gilthorpe, J. D., Bergenheim, T. A., & Svenningsson, A. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000271 · Cited by 166
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Varhaug, K. N., Barro, C., Bjørnevik, K., Myhr, K., Torkildsen, Ø., Wergeland, S., Bindoff, L. A., Kühle, J., & Vedeler, C. A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000422 · Cited by 164
Self-citationSerum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Thebault, S., Abdoli, M., Fereshtehnejad, S., Tessier, D. R., Tabard‐Cossa, V., & Freedman, M. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-67504-6 · Cited by 163
Towards a TDP-43-Based Biomarker for ALS and FTLD
Feneberg, E., Gray, E., Ansorge, O., Talbot, K., & Turner, M. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0947-6 · Cited by 154
Hviid, C. V. B., Knudsen, C. S., & Parkner, T. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1730434 · Cited by 143
Abdelhak, A., Hottenrott, T., Morenas‐Rodríguez, E., Suárez‐Calvet, M., Zettl, U. K., Haass, C., Meuth, S. G., Rauer, S., Otto, M., Tumani, H., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00280 · Cited by 149
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
Mariotto, S., Farinazzo, A., Magliozzi, R., Alberti, D., Monaco, S., & Ferrari, S. (2018) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12279 · Cited by 137
Serum neurofilament light chain levels are related to small vessel disease burden
Duering, M., Konieczny, M. J., Tiedt, S., Baykara, E., Tuladhar, A. M., Leijsen, E. V., Lyrer, P., Engelter, S. T., Gesierich, B., Achmüller, M., et al. (2018) · Journal of Stroke · doi:10.5853/jos.2017.02565 · Cited by 132
Self-citationNeurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Håkansson, I., Tisell, A., Cassel, P., Blennow, K., Zetterberg, H., Lundberg, P., Dahle, C., Vrethem, M., & Ernerudh, J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1249-7 · Cited by 128
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
Akgün, K., Kretschmann, N., Haase, R., Proschmann, U., Kitzler, H. H., Reichmann, H., & Ziemssen, T. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000555 · Cited by 124
The Evolution of Neurofilament Light Chain in Multiple Sclerosis
Ferreira‐Atuesta, C., Reyes, S., Giovanonni, G., & Gnanapavan, S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.642384 · Cited by 125
The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
Jung, Y., & Damoiseaux, J. S. (2023) · Brain · doi:10.1093/brain/awad267 · Cited by 123
Håkansson, I., Tisell, A., Cassel, P., Blennow, K., Zetterberg, H., Lundberg, P., Dahle, C., Vrethem, M., & Ernerudh, J. (2017) · European Journal of Neurology · doi:10.1111/ene.13274 · Cited by 117
Sejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
Maggi, P., Kühle, J., Schädelin, S., van der Meer, F., Weigel, M., Galbusera, R., Mathias, A., Lu, P., Rahmanzadeh, R., Benkert, P., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012326 · Cited by 112
Self-citationAlagaratnam, J., von Widekind, S., Francesco, D. D., Underwood, J., Edison, P., Winston, A., Zetterberg, H., & Fidler, S. J. (2021) · BMJ Neurology Open · doi:10.1136/bmjno-2021-000143 · Cited by 107
Bar‐Or, A., Thanei, G., Harp, C. T., Bernasconi, C., Bonati, U., Cross, A. H., Fischer, S. K., Gaetano, L., Hauser, S. L., Hendricks, R., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104662 · Cited by 107
Establishment of Neurofilament Light Chain Simoa Assay in Cerebrospinal Fluid and Blood
Hendricks, R., Baker, D., Brumm, J., Davancaze, T., Harp, C. T., Herman, A. H., von Büdingen, H.-C., Townsend, M. J., & Fischer, S. K. (2019) · Bioanalysis · doi:10.4155/bio-2019-0163 · Cited by 97
Plasma neurofilament light chain levels in Alzheimer’s disease
Zhou, W., Zhang, J., Ye, F., Xu, G., Su, H., Su, Y., & Zhang, X. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.04.027 · Cited by 95
CSF or Serum Neurofilament Light Added to α‐Synuclein Panel Discriminates Parkinson's From Controls
Oosterveld, L. P., Verberk, I. M. W., Majbour, N. K., El‐Agnaf, O. M. A., Weinstein, H. C., Berendse, H. W., Teunissen, C. E., & van de Berg, W. D. J. (2019) · Movement Disorders · doi:10.1002/mds.27897 · Cited by 96
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Manouchehrinia, A., Stridh, P., Khademi, M., Leppert, D., Barro, C., Michalak, Z., Benkert, P., Lycke, J., Alfredsson, L. S., Kappos, L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009571 · Cited by 93
Self-citationSerum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy
van Lieverloo, G. G. A., Wieske, L., Verhamme, C., Vrancken, A. F. J. E., van Doorn, P. A., Michalak, Z., Barro, C., van Schaik, I. N., Kühle, J., & Eftimov, F. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12319 · Cited by 92
Self-citationBiomarkers of multiple sclerosis: current findings
Harris, V., Tuddenham, J. F., & Sadiq, S. A. (2017) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s98936 · Cited by 92
Sørensen, P. S., Sellebjerg, F. T., Hartung, H.-P., Montalbán, X., Comi, G., & Tintoré, M. (2020) · Brain · doi:10.1093/brain/awaa145 · Cited by 99
Neurofilaments in disease: what do we know?
Gordon, B. A. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.001 · Cited by 82
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes
Costa, G. D., Martinelli, V., Sangalli, F., Moiola, L., Colombo, B., Radaelli, M., Leocani, L., Furlan, R., & Comı, G. (2019) · Neurology · doi:10.1212/wnl.0000000000006902 · Cited by 83
Neurofilaments and 10-year follow-up in multiple sclerosis
Bhan, A., Jacobsen, C., Myhr, K. M., Dalen, I., Lode, K., & Farbu, E. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518782005 · Cited by 79
Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation
Thebault, S., Booth, R. A., Rush, C., MacLean, H. J., & Freedman, M. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.654942 · Cited by 79
Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
Cai, L., & Huang, J. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s173280 · Cited by 77
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
Rosso, M., Gonzalez, C. T., Healy, B. C., Saxena, S., Paul, A., Bjørnevik, K., Kühle, J., Benkert, P., Leppert, D., Guttmann, C. R. G., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51060 · Cited by 75
Martin, S., McGlasson, S. L., Hunt, D. P. J., & Overell, J. R. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319190 · Cited by 79
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Reinert, M., Benkert, P., Wuerfel, J. T., Michalak, Z., Ruberte, E., Barro, C., Huppke, P., Stark, W., Kropshofer, H., Tomic, D., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000749 · Cited by 72
Self-citationRahimy, E., Li, F., Hagberg, L., Fuchs, D., Robertson, K., Meyerhoff, D. J., Zetterberg, H., Price, R. W., Gisslén, M., & Spudich, S. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix013 · Cited by 71
Seven day pre-analytical stability of serum and plasma neurofilament light chain
Altmann, P., Ponleitner, M., Rommer, P. S., Haslacher, H., Mucher, P., Leutmezer, F., Petzold, A., Wotawa, C., Lanzenberger, R., Berger, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90639-z · Cited by 68
Neurofilaments: The C-Reactive Protein of Neurology
Lambertsen, K. L., Soares, C. B., Gaist, D., & Nielsen, H. H. (2020) · Brain Sciences · doi:10.3390/brainsci10010056 · Cited by 66
Serum neurofilament light in MS: The first true blood-based biomarker?
Thebault, S., Bose, G., Booth, R. A., & Freedman, M. S. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458521993066 · Cited by 66
Kalm, M., Boström, M., Sandelius, Å., Eriksson, Y., Ek, C. J., Blennow, K., Björk‐Eriksson, T., & Zetterberg, H. (2017) · Brain Research · doi:10.1016/j.brainres.2017.05.011 · Cited by 67
Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis
Mariotto, S., Gajofatto, A., Zuliani, L., Zoccarato, M., Gastaldi, M., Franciotta, D. M., Cantalupo, G., Piardi, F., Polo, A., Alberti, D., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09306-z · Cited by 66
Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
Nitz, E., Smitka, M., Schallner, J., Akgün, K., Ziemssen, T., von der Hagen, M., & Tüngler, V. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51449 · Cited by 67
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
Sormani, M. P., Häring, D. A., Kropshofer, H., Leppert, D., Kundu, U., Barro, C., Kappos, L., Tomic, D., & Kühle, J. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.795 · Cited by 62
Self-citationBrureau, A., Blanchard-Bregeon, V., Pech, C., Hamon, S., Chaillou, P., Guillemot, J.-C., Barneoud, P., Bertrand, P., Pradier, L., Rooney, T., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.007 · Cited by 62
Varhaug, K. N., Vedeler, C. A., Myhr, K., Aarseth, J. H., Tzoulis, C., & Bindoff, L. A. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.12.003 · Cited by 63
Milo, R., Korczyn, A. D., Manouchehri, N., & Stüve, O. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519886943 · Cited by 61
Chhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60
SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
Paterson, R. W., Gabelle, A., Lucey, B. P., Barthélemy, N. R., Leckey, C. A., Hirtz, C., Lehmann, S., Sato, C., Patterson, B. W., West, T., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0222-0 · Cited by 60
Onatsu, J., Vanninen, R. L., Jäkälä, P., Mustonen, P. E., Pulkki, K. J., Korhonen, M., Hedman, M., Zetterberg, H., Blennow, K., Höglund, K., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.05.008 · Cited by 58
Costa, G. D., Martinelli, V., Moiola, L., Sangalli, F., Colombo, B., Finardi, A., Cinque, P. M., Kolb, E., Haghikia, A., Gold, R., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25437 · Cited by 58
A neuronal blood marker is associated with mortality in old age
Kaeser, S. A., Lehallier, B., Thinggaard, M., Häsler, L. M., Apel, A., Bergmann, C., Berdnik, D., Jeune, B., Christensen, K., Grönke, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00028-4 · Cited by 62
Blood Neurofilament Light in Progressive Multiple Sclerosis
Leppert, D., Kropshofer, H., Häring, D. A., Dahlke, F., Patil, A., Meinert, R., Tomic, D., Kappos, L., & Kühle, J. (2022) · Neurology · doi:10.1212/wnl.0000000000200258 · Cited by 55
Huss, A. M., Otto, M., Şenel, M., Ludolph, A. C., Abdelhak, A., & Tumani, H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00608 · Cited by 61
Ning, L., & Wang, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274565 · Cited by 65
Groß, C. C., Schulte‐Mecklenbeck, A., Steinberg, O. V., Wirth, T., Lauks, S., Bittner, S., Schindler, P., Baranzini, S. E., Groppa, S., Bellmann–Strobl, J., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade8560 · Cited by 54
Neurofilament as Neuronal Injury Blood Marker in Preeclampsia
Evers, K. S., Atkinson, A., Barro, C., Fisch, U., Pfister, M., Huhn, E. A., Lapaire, O., Kühle, J., & Wellmann, S. M. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10314 · Cited by 51
Self-citationHampel, H. J., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B. J., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 52
A roadmap to precision medicine for multiple sclerosis
Chitnis, T., & Prat, A. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519881558 · Cited by 53
Ziemssen, T., Arnold, D. L., Álvarez, E., Cross, A. H., Willi, R., Li, B., Kukkaro, P., Kropshofer, H., Ramanathan, K., Merschhemke, M. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852563 · Cited by 49
Long-term prognostic value of longitudinal measurements of blood neurofilament levels
Häring, D. A., Kropshofer, H., Kappos, L., Cohen, J. A., Shah, A. H., Meinert, R., Leppert, D., Tomic, D., & Kühle, J. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000856 · Cited by 49
York, E. N., Thrippleton, M. J., Meijboom, R., Hunt, D. P. J., & Waldman, A. D. (2022) · Brain Communications · doi:10.1093/braincomms/fcac088 · Cited by 46
Sandi, D., Fricska‐Nagy, Z., Bencsik, K., & Vécsei, L. (2021) · Molecules · doi:10.3390/molecules26113423 · Cited by 51
Newsome, S. D., Binns, C. C., Kaunzner, U. W., Morgan, S., & Halper, J. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00549-7 · Cited by 47
Fox, R. J., Cree, B., Seze, J. D., Gold, R., Hartung, H., Jeffery, D., Kappos, L., Montalbán, X., Weinstock‐Guttman, B., Singh, C. M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209357 · Cited by 50
Microfluidics-Based Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling
Li, Y., Li, D., Zhao, P., Nandakumar, K., Wang, L., & Song, Y. (2020) · Micromachines · doi:10.3390/mi11090787 · Cited by 45
Masvekar, R., Wu, T., Kosa, P. F., Barbour, C. R., Fossati, V., & Bielekova, B. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.11.032 · Cited by 44
No evidence of disease activity (NEDA) in multiple sclerosis - Shifting the goal posts
Pandit, L. (2019) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_159_19 · Cited by 45
Emerging imaging and liquid biomarkers in multiple sclerosis
Gill, A. J., Schorr, E. M., Gadani, S. P., & Calabresi, P. A. (2023) · European Journal of Immunology · doi:10.1002/eji.202250228 · Cited by 52
Wu, R., He, Q., Chen, H., Xu, M., Zhao, N., Xiao, Y., Tu, Q., Zhang, W., & Bi, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.115 · Cited by 42
Décard, B. F., Pham, M., & Grimm, A. M. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.10.028 · Cited by 42
Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse
Mills, E. A., Mirza, A., & Mao‐Draayer, Y. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00116 · Cited by 41
Schependom, J. V., Guldolf, K., D'hooghe, M. B., Nagels, G., & D’haeseleer, M. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0178-4 · Cited by 44
Rajda, C., Galla, Z., Polyák, H., Maróti, Z., Babarczy, K., Pukoli, D., & Vécsei, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082665 · Cited by 41
Iverson, G. L., Reddi, P. J., Posti, J. P., Kotilainen, A., Tenovuo, O. S., Öhman, J. E., Zetterberg, H., Blennow, K., & Luoto, T. M. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6341 · Cited by 40
Kušnierová, P., Zeman, D., Hradílek, P., Čábal, M., & Zapletalová, O. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22948 · Cited by 39
Serum neurofilament light chain and optical coherence tomography measures in MS
Tavazzi, E., Jakimovski, D., Kühle, J., Hagemeier, J., Ozel, O., Ramanathan, M. K., Barro, C., Bergsland, N., Tomic, D., Kropshofer, H., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000737 · Cited by 40
Self-citationKühle, J., Daizadeh, N. S., Benkert, P., Maceski, A. M., Barro, C., Michalak, Z., Sormani, M. P., Godin, J., Shankara, S., Samad, T. A., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211032348 · Cited by 37
Self-citationSerum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis
Bsteh, G., Berek, K., Hegen, H., Teuchner, B., Buchmann, A., Voortman, M. M., Auer, M., Wurth, S., Zinganell, A., Pauli, F. D., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519882279 · Cited by 37
Rival, M., Thouvenot, É., de Terdonck, L. D. T., Laurent‐Chabalier, S., Dematteï, C., Uygunoğlu, U., Castelnovo, G., Cohen, M., Okuda, D. T., Kantarci, O. H., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200044 · Cited by 37
Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
van Ballegoij, W. J. C., van de Stadt, S. I. W., Huffnagel, I. C., Kemp, S., Willemse, E. A. J., Teunissen, C. E., & Engelen, M. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51188 · Cited by 35
Mohammadinasr, M., Montazersaheb, S., Molavi, O., Kahroba, H., Talebi, M., Ayromlou, H., & Hejazi, M. S. (2023) · NeuroMolecular Medicine · doi:10.1007/s12017-023-08744-3 · Cited by 36
Fluid biomarker and electrophysiological outcome measures for progressive MS trials
Barro, C., Leocani, L., Leppert, D., Comi, G., Kappos, L., & Kuhle, J. (2017) · Multiple Sclerosis · doi:10.1177/1352458517732844 · Cited by 31
Self-citationThe role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis
Lycke, J., & Zetterberg, H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1400380 · Cited by 33
Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis
Thebault, S., Lee, H., Bose, G., Tessier, D. R., Abdoli, M., Bowman, M. A., Berard, J. A., Walker, L. A. S., Rush, C., MacLean, H. J., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51045 · Cited by 33
Liu, Q., Gao, Q., Zhang, Y., Li, Z., & Mei, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.123 · Cited by 32
Hviid, C. V. B., Gyldenholm, T., Lauridsen, S. V., Hjort, N., Hvas, A., & Parkner, T. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0532 · Cited by 32
Proschmann, U., Haase, R., Inojosa, H., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.715195 · Cited by 31
Metadata
- Authors
- Kuhle, J., Barro, C., Disanto, G., Mathias, A., Soneson, C., Bonnier, G., Yaldizli, Ö., Regeniter, A., Derfuss, T., Canales, M., Schluep, M., Du Pasquier, R., Krueger, G., & Granziera, C.
- Affiliations
- Neurology, Departments of Medicine, Clinical Research and Biomedicine, University Hospital of Basel, Basel, Switzerland
- University Hospital of Basel (CH)
- Neurocenter of Southern Switzerland, Ospedale Civico, Lugano, Switzerland
- Centre Hospitalier Universitaire Vaudois (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- Laboratory of Neuroimmunology, Center of Research in Neurosciences, Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland/Service of Neurology, Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland
- Advanced Clinical Imaging Technology Group, Siemens Healthcare IM BM PI, Lausanne, Switzerland/Healthcare Sector IM&WS S, Siemens Schweiz AG, Renens, Switzerland
- ORCID
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2016-07-11
- Volume
- 22
- Issue
- 12
- Pages
- 1550-1559
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2340550513
- Cited by
- 257
- References
- 36
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 21 · 2023: 26 · 2022: 22 · 2021: 29 · 2020: 35 · 2019: 41 · 2018: 21 · 2017: 24 · 2016: 7
- FWCI
- 28.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (131914, 154508)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- neurofilament light chain, serum biomarkers, relapsing-remitting multiple sclerosis, cerebrospinal fluid, white matter lesion volume, T1 and T2 relaxation, magnetization transfer ratio, normal-appearing white matter, disease severity, neuroinflammation, neurodegeneration
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Severity of Illness Index, Neurofilament Proteins, Multiple Sclerosis, Relapsing-Remitting, Young Adult, White Matter
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
